Skip to content

Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Migraine
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • Lyme Disease
      • Mpox (Monkey Pox)
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-4800
      • TNX-801
      • TNX-4200 CD45
    • Rare Disease
      • TNX-2900
    • Expanded Access Policy
  • Medicines
  • Clinical Trials
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • Investor Presentations
    • Scientific Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
      • Investor Presentations
      • Scientific Presentations
      • Program Specific Presentations
      • Conference Materials
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us
June 2024

ATC 2024: Extended Survival of 9- and 10-Gene Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade –Based Immunosuppression

June 2024

ATC 2024: Delayed Immune Tolerance for Cardiac Allografts in Nonhuman Primates by Targeting CD154, CD2, and CD28 Costimulation Pathways

June 2024

ASCP Annual Meeting 2024: Effects of Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) on Mood and Anxiety Symptoms in Fibromyalgia

May 2024

ASCP Annual Meeting 2024: Fibromyalgia-Type Long COVID

May 2024

ASCP Annual Meeting 2024: Acute Stress Disorder

April 2024

AACR Annual Meeting 2024: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody

April 2024

World Vaccine Congress 2024: Attenuation of the Horsepox Virus Platform as a Vaccine for Mpox/Smallpox (TNX-801)

March 2024

American Chemistry Society (ACS) Spring 2024: Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations

March 2024

Controversies in Fibromyalgia 2024: Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia: Results from the Phase 3 Randomized, Double-Blind, Placebo-Controlled RESILIENT Trial

March 2024

Controversies in Fibromyalgia: Tonmya* (TNX-102 SL) in Development for the Management of Fibromyalgia

Posts navigation

Older posts
Newer posts
Sign up for Email Alerts
  • Compliance
  • Privacy Policy
  • Terms of Service
  • Site Map

© 2026 Tonix Pharmaceuticals Holding Corp.